Secara global kanker paru merupakan tiga terbesar kasus penyakit kanker di dunia dan menempati urutan pertama sebagai penyebab kematian akibat penyakit kanker pada laki laki dan perempuan (Globocan, 2022) Di Indonesia, kanker paru menjadi penyebab utama kematian akibat kanker di samping kanker payudara dan kanker kolorektal (WHO, 2022). Kanker paru ditempatkan sebagai beban utama biaya pengobatan yang bersifat katastropik dengan menyerap anggaran besar dari total belanja kesehatan negara dalam Diasease Account 2023. Besaran biaya klaim penyakit kanker paru sangat ditentukan oleh berbagai faktor yang memengaruhi tingkat keparahan dan intensitas pemanfaatan layanan. Oleh karena itu diperlukan analisis untuk mengetahui faktor-faktor yang berhubungan dengan biaya kanker paru. Metode: Penelitian menggunakan Data Sampel BPJS Kesehatan dengan desain cross sectional. Hasil: Terdapat hubungan signifikan antara usia, jenis kelamin, segmen kepesertaan, hak kelas rawat, metastasis, kunjungan rawat inap, kunjungan rawat jalan, kepemilikan rumah sakit, tipe rumah sakit, dan wilayah regional FKRTL dengan biaya klaim. Faktor yang paling berhubungan yaitu metastasis (p value <0,001; AOR 11,045). Kesimpulan: Diperlukan peningkatan deteksi dini melalui skrining nasional, pemerataan akses, dan peninjauan tarif INA CBGs

Lung cancer is among the three most common cancers worldwide and remains the leading cause of cancer-related mortality in both men and women (GLOBOCAN, 2022). In Indonesia, lung cancer is one of the primary causes of cancer deaths, alongside breast and colorectal cancer (WHO, 2022). It also represents a major catastrophic health expenditure, accounting for a substantial proportion of national healthcare spending as reported in the Disease Account 2023. The magnitude of lung cancer treatment costs is influenced by various factors related to disease severity and healthcare utilization. Therefore, an analysis is needed to identify factors associated with lung cancer treatment costs. Methods: This study used secondary data from the BPJS Kesehatan Sample Data and employed a cross-sectional study design. Data were analyzed using bivariate and multivariate logistic regression analyses to identify factors associated with lung cancer claim costs. Results: Significant associations were found between age, sex, membership segment, inpatient class entitlement, metastasis status, inpatient visits, outpatient visits, hospital ownership, hospital type, and regional referral healthcare facility (FKRTL) location with lung cancer claim costs. Metastasis was identified as the factor most strongly associated with high claim costs (p-value < 0.001; AOR = 11.045). Conclusion: Strengthening early detection through a national lung cancer screening program, improving equitable access to healthcare services, and reviewing INA-CBGs tariffs are recommended to reduce the economic burden of lung cancer and improve the efficiency of healthcare financing under the National Health Insurance (JKN) system.